Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous protein solution for knee osteoarthritis
ACTRN12621000220864Phase 4Recruiting
- Sponsor
- Northland District Health Board
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 4, randomised trial in knee osteoarthritis (OA) comparing Autologous protein solution with Saline placebo control (2 arms). Primary endpoints: WOMAC overall score at 12 months, KOOS pain subscore at 12 months and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
autologous protein solution
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12621000220864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000220864.